Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead ...
PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...
VICTORIA, BC, Sept. 11, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-T) from The Globe and Mail including charting and trades.
CNW/ - ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging ...
Consistent improvement in patient reported outcomes with 10 of 11 evaluable patients in the first four cohorts experiencing a reduction in symptom (SDI 1) scores at 12 weeks The fourth cohort ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback